Omnicell Inc (OMCL)

Currency in USD
28.20
-0.06(-0.21%)
Closed·
After Hours
28.200.00(0.00%)
·
OMCL Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 8 days
Fair Value
Day's Range
27.8028.42
52 wk Range
22.6655.75
Key Statistics
Prev. Close
28.26
Open
28.3
Day's Range
27.8-28.42
52 wk Range
22.66-55.75
Volume
369.27K
Average Volume (3m)
605.02K
1-Year Change
0.78%
Book Value / Share
26.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OMCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.83
Upside
+55.44%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Omnicell Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Omnicell Inc Company Profile

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Omnicell Inc SWOT Analysis


Financial Rebound
Omnicell exceeds Q2 expectations, raising full-year guidance amid improved hospital capital expenditure, signaling a positive shift in the healthcare technology secto
Strategic Evolution
Delve into Omnicell's expansion into specialty pharmacy and the launch of XT Amplify, positioning the company for growth in advanced healthcare services
Operational Overhaul
Explore the potential impact of new COO Nnamdi Njoku on Omnicell's cost reduction efforts and operational efficiency, aiming for long-term profitability
Market Dynamics
Analyst targets range from $39 to $58, reflecting varied perspectives on Omnicell's ability to navigate industry challenges and capitalize on healthcare digitization trends
Read full SWOT analysis

Omnicell Inc Earnings Call Summary for Q1/2025

  • Omnicell's Q1 2025 EPS of $0.26 beat $0.21 forecast; revenue up $24M YoY to $270M, but stock fell 13.74% to $26.30
  • Non-GAAP EBITDA rose $13M YoY to $24M; company expects 2025 revenue of $1,115M-$1,155M and non-GAAP EPS of $1.00-$1.65
  • CEO emphasized focus on redefining medication management across healthcare; expansion into outpatient and specialty pharmacy markets
  • Tariffs estimated to impact non-GAAP EBITDA by $40M in 2025; supply chain relocation and component shipment acceleration planned
  • InvestingPro analysis suggests stock undervalued; analysts set price targets from $36 to $69 despite current market reaction
Last Updated: 06/05/2025, 15:08
Read Full Transcript

Compare OMCL to Peers and Sector

Metrics to compare
OMCL
Peers
Sector
Relationship
P/E Ratio
62.5x−4.2x−0.5x
PEG Ratio
0.32−0.300.00
Price/Book
1.1x2.6x2.6x
Price / LTM Sales
1.2x4.1x3.2x
Upside (Analyst Target)
43.3%31.9%42.7%
Fair Value Upside
Unlock−3.4%5.8%Unlock

Analyst Ratings

5 Buy
3 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.83
(+55.44% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
0.26 / 0.21
Revenue / Forecast
269.67M / 260.18M
EPS Revisions
Last 90 days

OMCL Income Statement

People Also Watch

47.850
SMR
+7.67%
126.04
CRWV
-2.87%
119.28
PHM
-1.56%
20.300
QBTS
+15.41%
130.72
LRN
+0.76%

FAQ

What Stock Exchange Does Omnicell Trade On?

Omnicell is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Omnicell?

The stock symbol for Omnicell is "OMCL."

What Is the Omnicell Market Cap?

As of today, Omnicell market cap is 1.32B.

What Is Omnicell's Earnings Per Share (TTM)?

The Omnicell EPS (TTM) is 0.46.

When Is the Next Omnicell Earnings Date?

Omnicell will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is OMCL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Omnicell Stock Split?

Omnicell has split 0 times.

How Many Employees Does Omnicell Have?

Omnicell has 3620 employees.

What is the current trading status of Omnicell (OMCL)?

As of 23 Jul 2025, Omnicell (OMCL) is trading at a price of 28.20, with a previous close of 28.26. The stock has fluctuated within a day range of 27.80 to 28.42, while its 52-week range spans from 22.66 to 55.75.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.